This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


ELIQUIS® (apixaban) dosing for
patients with DVT / PE

ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE

* As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).1

Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

  • No dose adjustment for DVT / PE patients, based on age, weight or those with mild-to-moderate renal impairment1
  • ELIQUIS should be used with caution in patients with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE1
  • ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis1
  • Liver function testing should be performed prior to initiating ELIQUIS1
ELIQUIS is a convenient, oral treatment for patients:

No initial injections or bridging with LMWH required.1

Missed dose: if a dose is missed, the patient should take ELIQUIS immediately and then continue with twice-daily intake as before.1

ELIQUIS can be taken with
or without food.1

FOOTNOTES

BD = Twice Daily   CrCl = Creatinine Clearance   DVT = Deep Vein Thrombosis   
LMWH = Low Molecular Weight Heparin   PE = Pulmonary Embolism

REFERENCE

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.